Stoke Therapeutics (STOK) said Tuesday that Edward Kaye is stepping down as chief executive, effective Wednesday.
The company said Kaye would continue to serve as an adviser to the company and remain a director of its board.
Ian Smith, currently a senior adviser to Bain Capital Life Sciences, has been named interim CEO.
Arthur Tzianabos, Stoke's board chairman, will also take on the role of interim executive chairman, supporting the transition and leading the search for a permanent CEO.